Multiple Sclerosis News Today Forums Forums Trials and Research Ocrevus fuels a sea change in the treatment of multiple sclerosis in U.S.

  • Ocrevus fuels a sea change in the treatment of multiple sclerosis in U.S.

    Posted by ms-news-today-moderator on July 2, 2018 at 7:04 am

    Genentech‘s Ocrevus (ocrelizumab), approved in March 2017, has fueled a sea change in the treatment of multiple sclerosis (MS) patients in the U.S., leading to an increased interest in disease-modifying therapies (DMTs) for progressive forms of MS.

    Now, other potential treatment choices for progressive MS forms will likely follow, including Novartis’ investigative oral treatment siponimod (BAF312), MedDay Pharmaceuticals‘ MD-1003, and AB Science‘s masitinib. Click here to read more: After Ocrevus Approval, New Therapies May Become Available for MS, Report Suggests

    Have you heard of these therapies? What do you think about them?

    replied 5 years, 9 months ago 1 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Log in to reply.